X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
Australia
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
Details:
Emifarma will be responsible for the initial stages of development and testing of the Company’s Mango ED products, including Mango ED, a combination of Tadalafil, Oxytocin, and L-Arginine, intended for the Mexican and Latin American markets.
Lead Product(s): Tadalafil,Oxytocin,L-Arginine
Therapeutic Area: Psychiatry/Psychology Product Name: Mango ED
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Mangoceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 12, 2024
Details:
The Company intends to use the net proceeds to finance the marketing and operational expenses associated with the planned marketing of its Mango ED, a combination of Tadalafil, Oxytocin, and L-Arginine that have been traditionally used to treat sexual dysfunction.
Lead Product(s): Tadalafil,Oxytocin,L-Arginine
Therapeutic Area: Psychiatry/Psychology Product Name: Mango ED
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Boustead Securities
Deal Size: $1.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 15, 2023
Details:
Mango (sildenafil citrate) mango-flavored, rapid dissolve tablet is a Phosphodiesterase-5 inhibitor, which is being indicated for the treatment of erectile dysfunction.
Lead Product(s): Sildenafil Citrate,Oxytocin,L-Arginine
Therapeutic Area: Psychiatry/Psychology Product Name: Mango
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2023
Details:
The partnership aims bring its flagship product, Mango, a combination of Tadalafil, Oxytocin, and L-Arginine that have been traditionally used to treat sexual dysfunction, to New York.
Lead Product(s): Tadalafil,Oxytocin,L-Arginine
Therapeutic Area: Psychiatry/Psychology Product Name: Mango
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Greater NY Chamber of Commerce
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 09, 2023
Details:
The proceeds will be used for the finalization of the late-stage development of the lead candidate ITM-11 (n.c.a. 177Lu-edotreotide), a targeted radiopharmaceutical currently being evaluated in phase III for the treatment of gastroenteropancreatic neuroendocrine tumors.
Lead Product(s): n.c.a. Lutetium-177-edotreotide,L-Arginine,Lysine
Therapeutic Area: Oncology Product Name: ITM-11
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Indigenous Critical Infrastructure Fund Canada
Deal Size: $36.3 million Upfront Cash: Undisclosed
Deal Type: Financing March 22, 2022
Details:
ITM-11, a targeted radionuclide therapy consisting of high-quality radioisotope, no-carrier-added lutetium-177 combined with somatostatin analog edotreotide is best standard of care for patients with neuroendocrine tumors.
Lead Product(s): n.c.a. Lutetium-177-edotreotide,L-Arginine,Lysine
Therapeutic Area: Oncology Product Name: ITM-11
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2022
Details:
The equity investment follows the licensing agreement between companies which provides GP with rights to develop, manufacture and commercialize ITM’s precision oncology radiopharmaceutical candidates, ITM-11 (n.c.a. 177Lu-edotreotide) and ITM-41 (n.c.a. 177Lu-zoledronate).
Lead Product(s): Lutetium-177-edotreotide,L-Arginine,Lysine
Therapeutic Area: Oncology Product Name: ITM-11
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Grand Pharmaceutical Group Limited
Deal Size: $588.4 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 16, 2022
Details:
ITM-11 (177Lu-edotreotide), a synthetic form of the peptide hormone somatostatin that targets neuroendocrine tumor-specific receptors demonstrated promising results in its trial for the treatment of hard-to-treat tumors.
Lead Product(s): n.c.a. Lutetium-177-edotreotide,L-Arginine,Lysine
Therapeutic Area: Oncology Product Name: ITM-11
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2022
Details:
Under the terms of the agreement, ITM grants GP an exclusive license for the ITM-11 (n.c.a. 177Lu-edotreotide) and ITM-41 (n.c.a. 177Lu-zoledronate), in the licensed territory and will support the supply of the pharmaceuticals needed for clinical and commercial activities.
Lead Product(s): Lutetium-177-edotreotide,L-Arginine,Lysine
Therapeutic Area: Oncology Product Name: ITM-11
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Grand Pharmaceutical Group Limited
Deal Size: $588.4 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 27, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
